Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.
BioPharma Dive13h
Axsome secures top drug’s future with Teva patent settlement
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.
manilatimes18h
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr - bupropion HCl) Patent Litigation
The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.
manilatimes18h
With No Competing Offers, Beacon Roofing's Board Stalls and Misleads
Beacon's recent filings indicate no viable third-party alternative to QXO's premium offer. Beacon's 14D-9 filing has not disclosed any competing offers, or even a single NDA being signed.